ChAdOx1-MVA 5T4 vaccine + Nivolumab Infusion [Opdivo]
Phase 1/2Terminated 0 views this week 0 watching💤 Quiet
Interest: 14/100
14
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Intermediate Risk Prostate Cancer
Conditions
Intermediate Risk Prostate Cancer, Castration-resistant Prostate Cancer
Trial Timeline
Dec 10, 2018 → Jun 24, 2020
NCT ID
NCT03815942About ChAdOx1-MVA 5T4 vaccine + Nivolumab Infusion [Opdivo]
ChAdOx1-MVA 5T4 vaccine + Nivolumab Infusion [Opdivo] is a phase 1/2 stage product being developed by Barinthus Biotherapeutics for Intermediate Risk Prostate Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT03815942. Target conditions include Intermediate Risk Prostate Cancer, Castration-resistant Prostate Cancer.
What happened to similar drugs?
1 of 3 similar drugs in Intermediate Risk Prostate Cancer were approved
Approved (1) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
9
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03815942 | Phase 1/2 | Terminated |
Competing Products
8 competing products in Intermediate Risk Prostate Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Roxadustat + Placebo | Astellas Pharma | Phase 3 | 32 |
| Adalimumab | AbbVie | Approved | 43 |
| venetoclax and ibrutinib (I+VEN) + FCR | AbbVie | Phase 2 | 35 |
| Durvalumab + Tremelimumab | AstraZeneca | Phase 2 | 35 |
| FTY720 + Oral Corticosteroid | Novartis | Phase 2 | 27 |
| LFG316 + Conventional Therapy | Novartis | Phase 2 | 35 |
| Myfortic + Decortin | Novartis | Phase 3 | 40 |
| Etavopivat | Novo Nordisk | Phase 2 | 27 |